Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;48(5):681-686.
doi: 10.1007/s15010-020-01438-z. Epub 2020 May 11.

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

Georg Härter  1 , Christoph D Spinner  2 , Julia Roider  3   4 , Markus Bickel  5 , Ivanka Krznaric  6 , Stephan Grunwald  6 , Farhad Schabaz  7 , Daniel Gillor  8 , Nils Postel  9 , Matthias C Mueller  10   11 , Markus Müller  12 , Katja Römer  13 , Knud Schewe  14 , Christian Hoffmann  14   15
Affiliations

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

Georg Härter et al. Infection. 2020 Oct.

Abstract

Introduction: Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population.

Methods: Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome.

Results: Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir.

Conclusions: This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.

Keywords: AIDS; Antiretroviral therapy; COVID-19; HIV infection; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Dr. Spinner reports and Dr. Spinner is PI in Remdesivir trials and several HIV registrational trials of Abbvie, Gilead, Janssen, MSD, ViiV. All other authors have declared nothing to disclose.

References

    1. World Health Organization (WHO) (2019) Coronavirus disease (COVID-19) outbreak situation. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337. doi: 10.1016/S1470-2045(20)30096-6. - DOI - PMC - PubMed
    1. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24:108. doi: 10.1186/s13054-020-2833-7. - DOI - PMC - PubMed
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed

MeSH terms